Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced two key improvements to the core capabilities of its Tapestri Platform intended to expand its accessibility and utility in the area of hematologic oncology (heme-onc) research.
You Might Also Like
Horizon as part of an Industry Advisory Committee led by YCharOS, Inc is providing HAP1 cell lines for antibody characterization enabling the research of the broader scientific community
Quanterix Receives FDA Emergency Use Authorization For SARS-CoV-2 N Protein Antigen Test
